2026 Q2 -tulosraportti
10 päivää sitten
‧48 min
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 22.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 22.7. | ||
2026 Q1 -tulosraportti 23.4. | ||
2025 Q4 -tulosraportti 11.2. | ||
2025 Q3 -tulosraportti 30.10.2025 | ||
2025 Q2 -tulosraportti 17.7.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·11 t sittenMedical breakthrough allows kidney transplant for patient with zero options The article from July 30 2026 should be positive for Imlifidase. The article describes a patient who was considered to have “zero options” due to extremely high levels of antibodies against donors. Researchers used an advanced immunotherapy to significantly reduce these antibodies and enable a kidney transplant. The treatment appears to be based on a more long-term “reprogramming” of the immune system, rather than a rapid breakdown of antibodies. For Imlifidase, I would assess the news as predominantly positive. It shows that: 1 the need for treatment for highly sensitized patients is great, 2 research in the field is very active. 3 the transplantation field is increasingly focusing on desensitization, 4 Imlifidase receives indirect confirmation that this is an important clinical area. The biggest risk for Imlifidase in the very long term is if cell therapies become simple, cheap, and can be widely used before transplantation. But with today's knowledge, these techniques appear to be complements rather than direct replacements. https://www.news-medical.net/news/20260730/Medical-breakthrough-allows-kidney-transplant-for-patient-with-zero-options.aspx- ·13 t sittenMy analysis of the situation Today's bullish hammer appears to have caught the bears in a classic bear trap. The strong close, together with high volume, provides clear confirmation that the buyers have taken control. Now, 35.74 is the decisive level. A breakout there would confirm a powerful bullish flag and open up for a significantly stronger rally. As long as the technical picture holds, momentum appears to be on the bulls' side. My opinion and not advice, 📈👇
Hansa has previously had a strong tendency to close gaps. Don't you see a greater probability that it will go down and close price 32? I sold on the news at price 41 because I believe I can get it cheaper before it rises again. - ·1 päivä sittenClassic Bull Trap and distribution (my opinion) After a bull trap (my opinion) above 40,50, see my previous posts, short selling has increased again along with likely some distribution. We have already seen large selling volumes, among others from insiders. Short positions have also been bought back somewhat at higher price levels, and they therefore have somewhat less risk of contributing to increased selling pressure in the market. Above the current price, there is resistance from investors holding loss positions. Those who bought the stock after SEB's recommendation are now at a loss. Short sellers also know that investors with certificates or high leverage are often more vulnerable. Their positions can therefore be relatively easily forced into selling, which can further benefit the short sellers' strategy. My opinion and not advice.
Everything else than PDUFA in December is utterly irrelevant. And a waste of time to concern oneself with. It is minus 80% or 3-5 doubling depending on the outcome. Then it can jump a little up and down along the way. - ·1 päivä sitten · MuokattuThere is ONE thing - and ONLY one - that determines whether this stock loses 80% or 3-5x in the next 6-12 months - and that is the decision from the FDA which is currently set for December 2026. And no one - absolutely NO ONE - has any idea what the FDA will decide. So it makes no sense to interpret this insignificant announcement. Let's say it's only 50% (we don't know that) he sells for 18 million - perhaps with a profit of 9 million (we don't know that either) - then he has boosted his personal finances with a decent amount - and is still part of the potential for an approval. If that's how it is, I could have done the same - I have actually also reduced my exposure a bit during the latest increase
No one knows the answer regarding fda or anything. But I understand well why one chooses to sell off at that price. Hansa will in no way 3-5 times in the next 6-12 months, maybe there can be an increase to around 50-60kr with an approved fda. But it's all about can it be sold in usa? After the sales figures of the last 5 years, it's not exactly something that confirms Hansa's own fantasy figures of 2 billion dollars in sales in usa. So we will see the same trading pattern: upon approval, it will rise sharply and then fall. As long as there is no control over sales or costs. They have supposedly sold the rights in eu for 1 billion, what would make the rights in usa worth 15 billion?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q2 -tulosraportti
10 päivää sitten
‧48 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·11 t sittenMedical breakthrough allows kidney transplant for patient with zero options The article from July 30 2026 should be positive for Imlifidase. The article describes a patient who was considered to have “zero options” due to extremely high levels of antibodies against donors. Researchers used an advanced immunotherapy to significantly reduce these antibodies and enable a kidney transplant. The treatment appears to be based on a more long-term “reprogramming” of the immune system, rather than a rapid breakdown of antibodies. For Imlifidase, I would assess the news as predominantly positive. It shows that: 1 the need for treatment for highly sensitized patients is great, 2 research in the field is very active. 3 the transplantation field is increasingly focusing on desensitization, 4 Imlifidase receives indirect confirmation that this is an important clinical area. The biggest risk for Imlifidase in the very long term is if cell therapies become simple, cheap, and can be widely used before transplantation. But with today's knowledge, these techniques appear to be complements rather than direct replacements. https://www.news-medical.net/news/20260730/Medical-breakthrough-allows-kidney-transplant-for-patient-with-zero-options.aspx
- ·13 t sittenMy analysis of the situation Today's bullish hammer appears to have caught the bears in a classic bear trap. The strong close, together with high volume, provides clear confirmation that the buyers have taken control. Now, 35.74 is the decisive level. A breakout there would confirm a powerful bullish flag and open up for a significantly stronger rally. As long as the technical picture holds, momentum appears to be on the bulls' side. My opinion and not advice, 📈👇Hansa has previously had a strong tendency to close gaps. Don't you see a greater probability that it will go down and close price 32? I sold on the news at price 41 because I believe I can get it cheaper before it rises again.
- ·1 päivä sittenClassic Bull Trap and distribution (my opinion) After a bull trap (my opinion) above 40,50, see my previous posts, short selling has increased again along with likely some distribution. We have already seen large selling volumes, among others from insiders. Short positions have also been bought back somewhat at higher price levels, and they therefore have somewhat less risk of contributing to increased selling pressure in the market. Above the current price, there is resistance from investors holding loss positions. Those who bought the stock after SEB's recommendation are now at a loss. Short sellers also know that investors with certificates or high leverage are often more vulnerable. Their positions can therefore be relatively easily forced into selling, which can further benefit the short sellers' strategy. My opinion and not advice.Everything else than PDUFA in December is utterly irrelevant. And a waste of time to concern oneself with. It is minus 80% or 3-5 doubling depending on the outcome. Then it can jump a little up and down along the way.
- ·1 päivä sitten · MuokattuThere is ONE thing - and ONLY one - that determines whether this stock loses 80% or 3-5x in the next 6-12 months - and that is the decision from the FDA which is currently set for December 2026. And no one - absolutely NO ONE - has any idea what the FDA will decide. So it makes no sense to interpret this insignificant announcement. Let's say it's only 50% (we don't know that) he sells for 18 million - perhaps with a profit of 9 million (we don't know that either) - then he has boosted his personal finances with a decent amount - and is still part of the potential for an approval. If that's how it is, I could have done the same - I have actually also reduced my exposure a bit during the latest increaseNo one knows the answer regarding fda or anything. But I understand well why one chooses to sell off at that price. Hansa will in no way 3-5 times in the next 6-12 months, maybe there can be an increase to around 50-60kr with an approved fda. But it's all about can it be sold in usa? After the sales figures of the last 5 years, it's not exactly something that confirms Hansa's own fantasy figures of 2 billion dollars in sales in usa. So we will see the same trading pattern: upon approval, it will rise sharply and then fall. As long as there is no control over sales or costs. They have supposedly sold the rights in eu for 1 billion, what would make the rights in usa worth 15 billion?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 22.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 22.7. | ||
2026 Q1 -tulosraportti 23.4. | ||
2025 Q4 -tulosraportti 11.2. | ||
2025 Q3 -tulosraportti 30.10.2025 | ||
2025 Q2 -tulosraportti 17.7.2025 |
2026 Q2 -tulosraportti
10 päivää sitten
‧48 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 22.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 22.7. | ||
2026 Q1 -tulosraportti 23.4. | ||
2025 Q4 -tulosraportti 11.2. | ||
2025 Q3 -tulosraportti 30.10.2025 | ||
2025 Q2 -tulosraportti 17.7.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·11 t sittenMedical breakthrough allows kidney transplant for patient with zero options The article from July 30 2026 should be positive for Imlifidase. The article describes a patient who was considered to have “zero options” due to extremely high levels of antibodies against donors. Researchers used an advanced immunotherapy to significantly reduce these antibodies and enable a kidney transplant. The treatment appears to be based on a more long-term “reprogramming” of the immune system, rather than a rapid breakdown of antibodies. For Imlifidase, I would assess the news as predominantly positive. It shows that: 1 the need for treatment for highly sensitized patients is great, 2 research in the field is very active. 3 the transplantation field is increasingly focusing on desensitization, 4 Imlifidase receives indirect confirmation that this is an important clinical area. The biggest risk for Imlifidase in the very long term is if cell therapies become simple, cheap, and can be widely used before transplantation. But with today's knowledge, these techniques appear to be complements rather than direct replacements. https://www.news-medical.net/news/20260730/Medical-breakthrough-allows-kidney-transplant-for-patient-with-zero-options.aspx
- ·13 t sittenMy analysis of the situation Today's bullish hammer appears to have caught the bears in a classic bear trap. The strong close, together with high volume, provides clear confirmation that the buyers have taken control. Now, 35.74 is the decisive level. A breakout there would confirm a powerful bullish flag and open up for a significantly stronger rally. As long as the technical picture holds, momentum appears to be on the bulls' side. My opinion and not advice, 📈👇Hansa has previously had a strong tendency to close gaps. Don't you see a greater probability that it will go down and close price 32? I sold on the news at price 41 because I believe I can get it cheaper before it rises again.
- ·1 päivä sittenClassic Bull Trap and distribution (my opinion) After a bull trap (my opinion) above 40,50, see my previous posts, short selling has increased again along with likely some distribution. We have already seen large selling volumes, among others from insiders. Short positions have also been bought back somewhat at higher price levels, and they therefore have somewhat less risk of contributing to increased selling pressure in the market. Above the current price, there is resistance from investors holding loss positions. Those who bought the stock after SEB's recommendation are now at a loss. Short sellers also know that investors with certificates or high leverage are often more vulnerable. Their positions can therefore be relatively easily forced into selling, which can further benefit the short sellers' strategy. My opinion and not advice.Everything else than PDUFA in December is utterly irrelevant. And a waste of time to concern oneself with. It is minus 80% or 3-5 doubling depending on the outcome. Then it can jump a little up and down along the way.
- ·1 päivä sitten · MuokattuThere is ONE thing - and ONLY one - that determines whether this stock loses 80% or 3-5x in the next 6-12 months - and that is the decision from the FDA which is currently set for December 2026. And no one - absolutely NO ONE - has any idea what the FDA will decide. So it makes no sense to interpret this insignificant announcement. Let's say it's only 50% (we don't know that) he sells for 18 million - perhaps with a profit of 9 million (we don't know that either) - then he has boosted his personal finances with a decent amount - and is still part of the potential for an approval. If that's how it is, I could have done the same - I have actually also reduced my exposure a bit during the latest increaseNo one knows the answer regarding fda or anything. But I understand well why one chooses to sell off at that price. Hansa will in no way 3-5 times in the next 6-12 months, maybe there can be an increase to around 50-60kr with an approved fda. But it's all about can it be sold in usa? After the sales figures of the last 5 years, it's not exactly something that confirms Hansa's own fantasy figures of 2 billion dollars in sales in usa. So we will see the same trading pattern: upon approval, it will rise sharply and then fall. As long as there is no control over sales or costs. They have supposedly sold the rights in eu for 1 billion, what would make the rights in usa worth 15 billion?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt